Women’s Health

Home » Women’s Health
Molecular Pathology Laboratory Network, Inc. (MPLN) has been on the forefront of laboratory medicine since its inception and inspired the genesis of women’s health testing using molecular diagnostics and technology. For more than 25 years, MPLN has continued to lead the way in specialty testing.

Liquid Cytology Testing

Test from a single liquid cytology specimen
(ThinPrep® PAP solution or SurePath™ Test Pack) for:

  • Chlamydia trachomatis (CT)
  • Neisseria gonorrhoeae (NG)
  • Human papillomavirus (HPV) and HPV genotyping (HPV G)
  • Trichomonas vaginalis (TV)
  • Herpes simplex virus (HSV)

(www.cdc.gov/std)

Aptima Trichomonas Vaginalis Assay

  • First FDA-cleared amplified nucleic acid test available to detect Trichomonas vaginalis
  • Requires a fraction of one organism for detection vs. the 10,000 organisms required for wet mount microscopy
  • Detects up to 100% of all Trichomonas infections
  • Available for use in both symptomatic and
    asymptomatic women

Molecular Diagnostic Experts in STI Testing and a Partner to Support Your Business

MPLN has been offering molecular diagnostic testing for HPV, CT, and NG for more than three decades. Because of MPLN’s significant involvement in STI related clinical trials, the laboratory has access to the latest advances in technology and automation which we share with our clients.

MPLN has always been at the forefront of laboratory medicine and inspired the genesis of women’s health testing using liquid cytology and molecular diagnostics. As a result of MPLN’s significant involvement in STI-related clinical trials, MPLN has access to the latest advances in technology and automation and shares these innovations with our pathology clients. MLPN continually updates clinical diagnostic testing platforms and assays to enable us to focus on better patient outcomes and reducing costs.

MPLN now offers the Hologic GenProbe APTIMA® HPV 16 18/45 Genotype Assay, which identifies the two most highly oncogenic and persistent high-risk HPV types known to cause high-grade cervical neoplasia. The assay also facilitates risk stratification of patients at greater risk for cervical disease to tailor care more appropriately.

Women’s health tests available from MPLN on ThinPrep® PAP and SurePathTM Test Pack liquid cytology media include HPV High Risk, HPV 16 14/45 Genotype, Chlamydia trachomatis, Neisseria gonorrhea, Herpes simplex, and Trichomonas vaginalis.

MPLN has been at the forefront of laboratory medicine and has been instrumental in developing women’s health testing through liquid cytology and molecular diagnostics. MPLN’s involvement in STI-related clinical trials has given us access to the latest technology and automation, which we share with our pathology clients. MPLN continuously updates its clinical diagnostic testing platforms and assays to enable better patient outcomes and reduce costs.

MPLN now offers the Hologic GenProbe APTIMA® HPV 16 18/45 Genotype Assay, which identifies the two most highly oncogenic and persistent high-risk HPV types known to cause high-grade cervical neoplasia. The assay also facilitates risk stratification of patients at greater risk for cervical disease in order to tailor care more appropriately.

MPLN provides women’s health tests on ThinPrep® PAP and SurePathTM Test Pack liquid cytology media. These tests include HPV High Risk, HPV 16 14/45 Genotype, Chlamydia trachomatis, Neisseria gonorrhea, Herpes simplex, and Trichomonas vaginalis.

APTIMA® Combo 2/HPV/Trichomonas

Higher sensitivity, greater specificity
  • FDA-cleared to detect Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (NC)
  • Second generation test eliminates inhibition and cross-reactivity problems and minimizes equivocal results.
  • Three technologies: target capture, transcription-mediated amplification, and dual kinetic assay

Aptima HPV Assay

Provides enhanced testing, refined results, and offers
the following benefits:

  • FDA approved to detect 14 high-risk types of human papillomavirus (HPV)
  • Based on a clinical evaluation of more than 10,000 U.S. women with normal cytology results, the APTIMA® HPV Assay demonstrated superior clinical specificity and sensitivity with 24% fewer false positives compared to competitor FDA approved DNA tests
  • Fewer false positives translates to fewer unnecessary colposcopies.

Hologic Gen-Probe APTIMA® HPV 16 18/45 Genotype Assay

  • Identifies the two most highly oncogenic and persistent high-risk HPV types known to cause high-grade cervical neoplasia
  • Facilitates risk-stratification of patients at greater risk for cervical disease in order to tailor care more appropriately
GET IN TOUCH

Have questions?

Contact our client services team today.